Fermer le menu

 

Osivax Appoints Vincent Bille as Chief Manufacturing Officer and Announces Manufacturing Progress for OVX836

  • Dr. Bille will oversee manufacturing scale-up for broad-spectrum influenza vaccine candidate OVX836 currently in Phase 2 clinical testing
  • Company achieved accreditation from Belgian authorities for OVX836 batch quality control laboratory in Liège Science Park

 

Lire le communiqué de presse

Plus d'infos